Testing Drug and Placebo Responses in Migraine Treatment
Tests an acute migraine drug and placebo in adults with episodic migraine.
Plain-language title generated from the registry record
Registry title: Trial Designs for Evaluating Migraine Treatment
Key facts
- Where
- Aarhus C and Aarhus N, DenmarkSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06617832, who can take part
Where in Denmark
- Dept. of Psychology and Behavioural SciencesAarhus C, DenmarkNot yet recruiting
- Department of Neurology, Aarhus University HospitalAarhus N, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT06617832
- Record updated
- 13 April 2026
- Original description
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.Read full original descriptionShow less
Trial Designs for Evaluating Migraine Treatment
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.
Inclusion: Adults (18-65 years); ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria; Known episodic migraine (≥ 1 and \< 15 headache days with features of migraine on at least 2-8 days per month for \> 3 months) with and without aura and diagnosed before age 50; Previous or active use of triptans as acute treatment for migraine; Ability to speak and read Danish.
Exclusion: Other concomitant primary headache types except for infrequent tension-type headache; Use of illegal psychotropic drugs less than a week before participation in the study; regarding cannabis: less than four weeks before participation in the study; Chronic migraine or history of chronic migraine in the last 12 months; Secondary headache disorders including medication overuse headache; Severe psychiatric, vascular or liver diseases; Current substance use disorder; Cardiac pacemaker or implanted or wearable defibrillator; Current use of preventive migraine treatment (i.e., onabotulinum toxin A, and/or Calcitonin gene-related peptide (CGRP) monoclonal antibodies) (however, stable medical treatment with other migraine prophylactic agents is permitted, e.g. antidepressant, calcium channel blockers, beta blockers and antiepileptic drugs, 4 weeks prior to inclusion until the completion of participation in the study); Opioid or barbiturate use in the month preceding screening; Contraindications or inability to tolerate triptans; Implanted metallic or electronic device in the head; Current pregnancy or planned pregnancy (confirmed by pregnancy test and by use of safe contraception as defined by the Danish Medicines Agency) and lactation.